

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, or claims in the application:

**Listing of Claims**

1. (Currently Amended): A method for treatment of a patient suffering from major depressive disorder, the said method comprising administering to said patient at a time selected from the group consisting of, as an initial treatment, as soon as possible and upon presentation of said patient to a physician or other health care provider an effective amount of an antidepressant, wherein said antidepressant is a newer antidepressant, and wherein said newer antidepressant is defined as an antidepressant excluding tricyclic antidepressants, tetracyclic antidepressants and permanent inhibitors of monoamine oxidase in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of a typical antipsychotic drug, an atypical antipsychotic drug, and a dopamine system stabilizer, and wherein said major depressive disorder categorized as non-treatment resistant and non-psychotic.

2. (Currently Amended): A method for treatment of a patient suffering from unipolar depression, the said method comprising administering to said patient at a time selected from the group consisting of, as an initial treatment, as soon as possible and upon presentation of said patient to a physician or other health care provider an effective amount of an antidepressant, wherein said antidepressant is a newer antidepressant, and wherein said newer antidepressant is defined as an antidepressant excluding tricyclic antidepressants, tetracyclic antidepressants and permanent inhibitors of monoamine oxidase in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of a typical antipsychotic drug, an atypical antipsychotic drug, and a dopamine system stabilizer, and wherein said unipolar depression categorized as non-treatment resistant and non-psychotic.

3. (Currently Amended): A method for treatment of a non-psychotic patient ~~selected from the group consisting of (a) a patient having cognitive distortions with functional impairment or health hazards, wherein the said method comprising administering to said patient as an initial treatment or as soon as possible, or upon presentation to a physician or a health care provider, or and (b) of a patient undergoing smoking cessation or nicotine withdrawal, the method comprising wherein in either case (a) or (b) the method includes administering to said non-psychotic patient an effective amount of an antidepressant, wherein said antidepressant is a newer antidepressant, and wherein said newer~~

antidepressant is defined as an antidepressant excluding tricyclic antidepressants, tetracyclic antidepressants and permanent inhibitors of monoamine oxidase in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of a typical antipsychotic drug, an atypical antipsychotic drug, and a dopamine system stabilizer, and wherein said antipsychotic drug is administered at a low dose.

4. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is an atypical antipsychotic.

5. (Original): The method of Claim 4 wherein said atypical antipsychotic drug is selected from the group consisting of quetiapine, risperidone, ziprasidone, and pharmaceutically acceptable salts thereof.

6. (Previously presented): The method of Claim 4 wherein said atypical antipsychotic drug is selected from the group consisting of olanzapine, iloperidone, ~~Org-5222~~, melperone, amperozide, ~~SM-9018, JL-13~~, and pharmaceutically acceptable salts thereof.

7. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is a dopamine system stabilizer.

8. (Original): The method of Claim 7, wherein said dopamine system stabilizer is aripiprazole, or pharmaceutically acceptable salts thereof.

9. (Currently Amended): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is selected from the group consisting of perphenazine, trifluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride, and wherein said an antipsychotic is administered at a low dose.

10. (Currently Amended): The method of Claims ~~9, 1, 2, or 3, wherein said antidepressant is~~ selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, and wherein said atypical antipsychotic drug is selected from the group consisting of ~~perphenazine, trifluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride.~~ ~~risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole.~~

11. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is selected from the group consisting of serotonin reuptake inhibitors, a selective norepinephrine reuptake inhibitors, combined action SSRI/SNRI, serotonin-2 antagonist/reuptake inhibitors, an antidepressant with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, an antidepressant with serotonin/norepinephrine/dopamine reuptake inhibition and an antidepressant with norepinephrine and dopamine reuptake inhibition.

12. (Currently Amended): The method of Claims 1, 2, or 3, wherein said antidepressant is selected from the group consisting of 5-HT-1alpha antagonist, 5-HT-1beta antagonist, 5-HT1A receptor agonists, 5-HT1A receptor agonists and antagonists, 5-HT2 receptor antagonists, viloxazine hydrochloride, dehydroepiandrosterone, NMDA receptor antagonists, AMPA receptor potentiators, substance P antagonists/ neurokinin-1 receptor antagonists, nonpeptide Substance P antagonist, neurokinin 2 antagonists, neurokinin 3 antagonists, corticotropin-releasing factor receptor antagonists, antiglucocorticoid medications, glucocorticoid receptor antagonists, cortisol blocking agents, nitric oxide synthesize inhibitors, inhibitors of phosphodiesterase, enkephalinase inhibitors, GABA-A receptor agonists, free radical trapping agents, atypical MAOI's, selective MAOI inhibitors, hormones, folic acid, leucovorin, tramadol, and tryptophan.

13. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is a selective serotonin reuptake inhibitor.

14. (Currently Amended): The method of Claim 11, wherein the said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

15. (Currently Amended): The method of Claim 11, wherein the said antidepressant is clomipramine.

16. (Currently Amended): The method of Claims 1, 2, or 3, 10, wherein said antidepressant is fluoxetine and said antipsychotic is risperidone.

17. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluoxetine and said antipsychotic is quetiapine.

18. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluoxetine and said antipsychotic is olanzapine.

19. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluoxetine and said antipsychotic is aripiprazole.

20. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is paroxetine and said antipsychotic is risperidone.

21. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is paroxetine and said antipsychotic is quetiapine.

22. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is paroxetine and said antipsychotic is olanzapine.

23. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is paroxetine and said antipsychotic is aripiprazole.

24. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is sertraline and said antipsychotic is risperidone.

25. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is sertraline and said antipsychotic is quetiapine.

26. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is sertraline and said antipsychotic is olanzapine.

27. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is sertraline and said antipsychotic is aripiprazole.

28. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluvoxamine and said antipsychotic is risperidone.

29. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluvoxamine and said antipsychotic is quetiapine.

30. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluvoxamine and said antipsychotic is olanzapine.

31. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluvoxamine and said antipsychotic is aripiprazole.

32. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluoxetine and said antipsychotic is ziprasidone.

33. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is paroxetine and said antipsychotic is ziprasidone.

34. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is sertraline and said antipsychotic is ziprasidone.

35. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein said antidepressant is fluvoxamine and said antipsychotic is ziprasidone.

36. (Currently Amended): The method of Claims ~~1, 2, or 3,~~ 10, wherein the said antipsychotic is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, and the effective amount is from 0.5mg to 4mg for risperidone, from 25mg to 400mg for quetiapine, from 2.5mg to 10mg for olanzapine, from 10mg to 40 mg for ziprasidone, and 2.5mg to 15 mg for aripiprazole.

37. (Currently Amended): The method of Claims 1, 2, or 3, wherein an effective amount of the said antidepressant is its recommended therapeutic dose, or its effective starting dose.

38. (Original): The method of Claims 1, 2, or 3, wherein the administration is oral.

39. (Cancelled)

40. (Cancelled)

41. (Currently Amended): The method of Claims 1 or 2, wherein said treatment is given for preventing resisting suicide.

42. (Currently Amended): The method of Claims 1 or 2, wherein said treatment is given effected for at least one of the group consisting of preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against inhibiting the development of tolerance toward the said antidepressant, or remedying the development of tolerance toward the said antidepressant, to provide providing a neuroprotective effect, to avoid avoiding a paradoxical effect of said antidepressant to sensitize sensitizing said patients to said depression, to avoid avoiding worsening of said depression from the said antidepressant, or treat treating worsening of said depression from the said antidepressant, to treat and treating residual symptoms of said depression, or for preventing the development of delusional/psychotic depression.

43. (Currently amended): The method of Claims 1, or 2 or 3, wherein said treatment is given at a time selected from the group consisting of, as initial treatment or as soon as possible, or upon presentation to a physician or a health care provider for preventing resisting suicide.

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Currently Amended): The method of ~~Claims 16 to 35~~ Claim 1, wherein said treatment is given effected for at least one of the group consisting of preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against inhibiting the development of tolerance toward the said antidepressant, or remediying the development of tolerance toward the said antidepressant, to provide providing a neuroprotective effect, to avoid avoiding a paradoxical effect of the said antidepressant to sensitize sensitizing said patients to said depression, to avoid avoiding worsening of said depression from the said antidepressant, or treat treating worsening of said depression from the said antidepressant, to treat and treating residual symptoms of said depression, or for preventing the development of delusional/psychotic depression.

49. (Currently Amended): The method of Claim 3, wherein said treatment is given for cognitive distortion(s) distortions, when the cognitive distortion(s) distortions lead to functional impairment, or a serious health hazard as an initial treatment, for a patient suffering from major depressive disorder, and for resisting suicide, and wherein said major depressive disorder categorized as non-treatment resistant and non-psychotic.

50. (Original): The method of Claim 3, wherein treatment is given for smoking cessation or nicotine withdrawal.

51. (Currently Amended): The method of Claim 13, wherein the said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, ~~bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproctate~~ and pharmaceutically acceptable salts thereof, and wherein said atypical antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole.

52. (Currently Amended): The method of Claim 13, wherein the said antidepressant is clomipramine, and wherein said atypical antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole.

53. (Currently Amended): The method of Claim 2, wherein said treatment is given effected for at least one of the group consisting of preventing inhibiting disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against inhibiting the development of tolerance toward the antidepressant, or remedying the development of tolerance toward the antidepressant, to provide providing a neuroprotective effect, to avoid avoiding a paradoxical effect of said antidepressant to sensitize sensitizing said patients to said depression, to avoid inhibiting worsening of said depression from the said antidepressant, and or treat treating worsening of said depression from the said antidepressant, to treat and treating residual symptoms of depression, or for preventing the development of delusional/psychotic depression.

54. (Currently Amended): The method of Claim 3, 49, wherein said treatment is given effected for at least one of the group consisting of preventing inhibiting disease progression, modifying the course of said depression major depressive disorder, delaying/preventing relapse, preventing the recurrence of depression, protecting against inhibiting the development of tolerance toward the said antidepressant, or remedying the development of tolerance toward the said antidepressant, to provide providing a neuroprotective effect, to avoid avoiding a paradoxical effect of said antidepressant to sensitize sensitizing said patients to said depression major depressive disorder, to avoid avoiding worsening of said depression major depressive disorder, from the said antidepressant, or treat treating worsening of said depression major depressive disorder from the said antidepressant, treat and treating residual symptoms of said depression major depressive disorder, or for preventing the development of delusional/psychotic depression.

55. (Currently amended): The method of Claim 1 including wherein said treatment is effected for treating substantially all of said patients treated by said physician or other health care provider by said method, wherein said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.

56. (Previously presented): The method of Claim 1 including treating a plurality of said patients by said method, wherein said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.

57. (Currently amended): The method of Claim 2 including wherein said treatment is effected for treating substantially all of said patients treated by said physician or other health care provider by said

method, wherein ~~said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.~~

58. (Previously presented): The method of Claim 2 including treating a plurality of said patients by said method, wherein said antipsychotic drug is administered at a low dose, and said treatment is given for resisting suicide.

59. (Currently amended): The method of Claims 1, 2, wherein said treatment is given for resisting suicide, and wherein said treatment is given for the benefit of the group of said patients being treated by said physician or health care provider.

60. (Currently amended): The method of Claims 55, 56, 57, or 58 wherein said treatment is given for the benefit of the group of said patients being treated by said physician or health care provider.

61. (Currently amended): The method of Claim 3, wherein said treatment is given for resisting suicide.

62. (Currently amended): The method of Claim 3, wherein said treatment is given for resisting suicide, and wherein said treatment is given for the benefit of the group.

63. (Previously presented): The method of Claims 55, 57 or 61, wherein said antipsychotic drug is an atypical antipsychotic.

64. (Previously presented): The method of Claims 55, 57 or 61, wherein said atypical antipsychotic drug is selected from the group consisting of quetiapine, risperidone, ziprasidone, and pharmaceutically acceptable salts thereof.

65. (Currently amended): The method of Claims 1, 2, 55, 57 or 61, wherein ~~the~~ said antipsychotic is the active metabolite of risperidone.

66. (Previously presented): The method of Claims 55, 57 or 61, wherein said atypical antipsychotic drug is selected from the group consisting of olanzapine, iloperidone, melperone, amperozide, and pharmaceutically acceptable salts thereof.

67. (Previously presented): The method of Claims 55, 57 or 61, wherein said antipsychotic drug is a dopamine system stabilizer.

68. (Previously presented): The method of 55, 57 or 61, wherein said dopamine system stabilizer is aripiprazole, or pharmaceutically acceptable salts thereof.

69. (Previously presented): The method of 55, 57 or 61, wherein said antipsychotic drug is selected from the group consisting of perphenazine, trifluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride.

70. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is selected from the group consisting of serotonin reuptake inhibitors, a selective norepinephrine reuptake inhibitors, combined action SSRI/SNRI, serotonin-2 antagonist/reuptake inhibitors, an antidepressant with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, an antidepressant with serotonin/norepinephrine/dopamine reuptake inhibition and an antidepressant with norepinephrine and dopamine reuptake inhibition.

71. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is selected from the group consisting of 5-HT-1alpha antagonist, 5-HT-1beta antagonist, 5-HT1A receptor agonists, 5-HT1A receptor agonists and antagonists, 5-HT2 receptor antagonists, ~~viloxazine hydrochloride~~, dehydroepiandrosterone, NMDA receptor antagonists, AMPA receptor potentiators, substance P antagonists/ neurokinin-1 receptor antagonists, nonpeptide Substance P antagonist, neurokinin 2 antagonists, neurokinin 3 antagonists, corticotropin-releasing factor receptor antagonists, antiglucocorticoid medications, glucocorticoid receptor antagonists, cortisol blocking agents, nitric oxide synthesize inhibitors, inhibitors of phosphodiesterase, enkephalinase inhibitors, GABA-A receptor agonists, ~~free radical trapping agents~~, atypical MAOI's, selective MAOI inhibitors, hormones, folic acid, leucovorin, tramadol, and tryptophan.

72. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is a selective serotonin reuptake inhibitor.

73. (Currently amended): The method of 55, 57 or 61, wherein the said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

74. (Currently amended): The method of 55, 57 or 61, wherein the said antidepressant is clomipramine.

75. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is risperidone.

76. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is quetiapine.

77. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is olanzapine.

78. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is aripiprazole.

79. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is risperidone.

80. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is quetiapine.

81. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is olanzapine.

82. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is aripiprazole.

83. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is risperidone.

84. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is quetiapine.

85. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is olanzapine.

86. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is aripiprazole.

87. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is risperidone.

88. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is quetiapine.

89. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is olanzapine.

90. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is aripiprazole.

91. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluoxetine and said antipsychotic is ziprasidone.

92. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is paroxetine and said antipsychotic is ziprasidone.

93. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is sertraline and said antipsychotic is ziprasidone.

94. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is fluvoxamine and said antipsychotic is ziprasidone.

95. (Currently amended): The method of Claims 55, 57 or 61, wherein ~~the~~ said antipsychotic is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, and the effective amount is from 0.5mg to 4mg for risperidone, from 25mg to 400mg for quetiapine, from 2.5mg to 10mg for olanzapine, from 10mg to 40 mg for ziprasidone, and 2.5mg to 15 mg for aripiprazole.

96. (Currently amended): The method of Claims 55, 57 or 61, wherein an effective amount of ~~the~~ said antidepressant is its recommended therapeutic dose, or its effective starting dose.

97. (Previously presented): The method of Claims 55, 57 or 61, wherein the administration is oral.

98. (Currently amended): The method of Claims 55, 57 or 61, wherein said treatment is effected for at least one of the group consisting of delaying relapse; ~~preventing~~ resisting relapse; and ~~preventing~~ resisting the recurrence of said depression.

99. (Currently amended): The method of Claims 55, 57 or 61, wherein said treatment is effected for at least one of the group consisting of protecting against the development of tolerance toward the antidepressant; and remedying the development of tolerance toward ~~the~~ said antidepressant.

100. (Currently amended): The method of Claims 1, 2, 55, 57 or 61, wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of ~~the~~ said antidepressant to sensitizing said patients to said depression; treating a paradoxical effect of said antidepressant to sensitizing said patients to said depression; for avoiding worsening of said depression from ~~the~~ said antidepressant; and treating worsening of said depression from ~~the~~ said antidepressant.

101. (Currently amended): The method of Claims 1, 2, 55, 57 or 61, wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of said antidepressant sensitizing said patients to said depression and causing suicide; avoiding a paradoxical effect of said antidepressant sensitizing said patients to said depression and causing suicidal ideation; treating a paradoxical effect of said antidepressant sensitizing said patients to said depression and causing suicide; treating a

paradoxical effect of said antidepressant sensitizing said patients to said depression and causing suicidal ideation; avoiding worsening of said depression from the said antidepressant and causing suicide; avoiding worsening of said depression from the said antidepressant and causing suicidal ideation; treating worsening of said depression from the said antidepressant and causing suicide; and treating worsening of said depression from the said antidepressant and causing suicidal ideation.

102. (Currently amended): The method of Claims 55, 57 or 61, wherein said treatment is given for providing a neuroprotective effect.

103. (Currently amended): The method of Claims 55, 57 or 61, wherein said treatment is given for treating residual symptoms of said depression.

104. (Currently amended): The method of Claims 55, 57 or 61, wherein the said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, fomoxetine, alaproclate and pharmaceutically acceptable salts thereof.

105. (Currently amended): The method of Claims 55, 57 or 61, wherein the said antidepressant is clomipramine.

106. (Previously presented): The method of Claims 55, 57 or 61, wherein said antidepressant is ketamine.

107. (Currently amended): The method of Claims 55, 57 or 61, wherein said antidepressant is ketamine, and wherein the said antipsychotic are selected from the group consisting of perphenazine, tripfluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride.

108. (Currently amended): The method of Claims 55, 57 or 61, wherein said antidepressant is ketamine, and wherein the said antipsychotic are selected from the group consisting of risperidone, quetiapine, olanzapine, ziprazidone, and aripiprazole, and the effective amount is from 0.5mg to 4 mg for risperidone, from 25mg to 400 mg for quetiapine, from 2.5mg to 10 mg for olanzapine, from 10-40mg for ziprazidone, and 2.5mg to 15mg for aripiprazole.

109. (Currently amended): A method for treatment of a patient suffering from major depressive disorder, the said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is effected for at least one of the group consisting of delaying relapse; preventing resisting relapse; and preventing resisting the recurrence of said depression.

110. (Currently amended): A method for treatment of a patient suffering from unipolar depression, the said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of delaying relapse; preventing resisting relapse; and preventing resisting the recurrence of said depression.

111. (Currently amended): A method for treatment of a patient suffering from major depressive disorder, the said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is effected for at least one of the

group consisting of protecting against development of tolerance toward ~~the~~ said antidepressant; and remedying the development of tolerance toward ~~the~~ said antidepressant.

112. (Currently amended): A method for treatment of a patient suffering from unipolar depression, ~~the~~ said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of protecting against development of tolerance toward ~~the~~ said antidepressant; and remedying the development of tolerance toward ~~the~~ said antidepressant.

113. (Currently amended): A method for treatment of a patient suffering from major depressive disorder, ~~the~~ said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of said antidepressant to-sensitizing said patients to said depression; treating a paradoxical effect of said antidepressant to-sensitizing said patients to said depression; for avoiding worsening of said depression from ~~the~~ said antidepressant; and treating worsening of said depression from ~~the~~ said antidepressant.

114. (Currently amended): A method for treatment of a patient suffering from unipolar depression, ~~the~~ said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine,

duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of said antidepressant to-sensitizing said patients to said depression; treating a paradoxical effect of said antidepressant to-sensitizing said patients to said depression; for avoiding worsening of said depression from the said antidepressant; and treating worsening of said depression from the said antidepressant.

115. (Currently amended): a method for treatment of a patient suffering from major depressive disorder, the said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of said antidepressant to-sensitizing said patients to said depression and causing suicide; avoiding a paradoxical effect of said antidepressant to-sensitizing said patients to said depression and causing suicidal ideation; treating a paradoxical effect of said antidepressant to-sensitizing said patients to said depression and causing suicide; treating a paradoxical effect of said antidepressant to-sensitizing said patients to said depression and causing suicidal ideation; avoiding worsening of said depression from the said antidepressant and causing suicide; avoiding worsening of said depression from the said antidepressant and causing suicidal ideation; treating worsening of said depression from the said antidepressant and causing suicide; and treating worsening of said depression from the said antidepressant and causing suicidal ideation.

116. (Currently amended): A method for treatment of a patient suffering from unipolar depression, the said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine,

duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of said antidepressant to-sensitizing said patients to said depression and causing suicide; avoiding a paradoxical effect of said antidepressant to-sensitizing said patients to said depression and causing suicidal ideation; treating a paradoxical effect of said antidepressant to sensitizing said patients to said depression and causing suicide; treating a paradoxical effect of said antidepressant to-sensitizing said patients to said depression and causing suicidal ideation; avoiding worsening of said depression from the said antidepressant and causing suicide; avoiding worsening of said depression from the said antidepressant and causing suicidal ideation; treating worsening of said depression from the said antidepressant and causing suicide; and treating worsening of said depression from the said antidepressant and causing suicidal ideation.

117. (Currently amended): A method for treatment of a patient suffering from major depressive disorder, the said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, said major depressive disorder categorized as non-treatment resistant and non-psychotic, and wherein said treatment is given for treating residual symptoms of said depression.

118. (Currently amended): A method for treatment of a patient suffering from unipolar depression, the said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof, in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine,

ziprasidone and aripiprazole, said unipolar depression categorized as non-treatment resistant and non-psychotic; and wherein said treatment is given for treating residual symptoms of depression.

119. (New): A method for treatment of a patient suffering from unipolar depression, said method comprising administering to said patient an effective amount of an antipsychotic drug wherein said antipsychotic drug is selected from the group consisting of an atypical antipsychotic drug, and a dopamine system stabilizer, wherein said treatment is effected for resisting suicide, and wherein said unipolar depression categorized as non-treatment resistant and non-psychotic.

120. (New): The method of Claim 119, wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant sensitizing patients to depression; treating a paradoxical effect of antidepressant sensitizing patients to depression; for avoiding worsening of depression from the antidepressant; and treating worsening of depression from the antidepressant.

121. (New): The method of Claim 119, wherein said treatment is effected at a time selected from the group consisting of, as an initial treatment, as soon as possible and upon presentation of said patient to a physician or other health care provider, and wherein said atypical antipsychotic drug or said dopamine system stabilizer is administered at a low dose.

122. (New): The method of Claims 119, 120, 121, wherein said atypical antipsychotic or said dopamine system stabilizer is selected from the group consisting of risperidone, olanzapine, ziprasidone and aripiprazole, and the effective amount is from 0.5mg to 4mg for risperidone, from 2.5mg to 10mg for olanzapine, from 10mg to 40 mg for ziprasidone, and 2.5mg to 15 mg for aripiprazole.

123. (New): The method of Claims 119, 120, 121, wherein said atypical antipsychotic is quetiapene, and the effective amount is from 25mg to 400mg.

124. (New): The method of Claim 10, wherein said treatment is selected as the first choice of treatment, and said treatment is effected for resisting suicide.

125. (New): The method of Claim 49, wherein said antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproctate and pharmaceutically acceptable salts thereof, and wherein said atypical antipsychotic drug is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole.

126. (New): A method for treatment of a patient having cognitive distortions with functional impairment or health hazards, wherein said patient is suffering from major depressive disorder, wherein said major depressive disorder categorized as non-treatment resistant and non-psychotic, wherein said method comprising administering to said patient an effective amount of an antidepressant, wherein said antidepressant is selected from the group consisting of serotonin reuptake inhibitors, a selective norepinephrine reuptake inhibitors, combined action SSRI/SNRI, serotonin-2 antagonist/reuptake inhibitors, an antidepressant with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, an antidepressant with serotonin/norepinephrine/dopamine reuptake inhibition, an antidepressant with norepinephrine and dopamine reuptake inhibition, 5-HT-1alpha antagonist, 5-HT-1beta antagonist, 5-HT1A receptor agonists, 5-HT1A receptor agonists and antagonists, 5-HT2 receptor antagonists, viloxazine hydrochloride, dehydroepiandrosterone, NMDA receptor antagonists, AMPA receptor potentiators, substance P antagonists/ neurokinin-1 receptor antagonists, nonpeptide Substance P antagonist, neurokinin 2 antagonists, neurokinin 3 antagonists, corticotropin-releasing factor receptor antagonists, antiglucocorticoid medications, glucocorticoid receptor antagonists, cortisol blocking agents, nitric oxide synthesize inhibitors, inhibitors of phosphodiesterase, enkephalinase inhibitors, GABA-A receptor agonists, free radical trapping agents, atypical MAOI's, selective MAOI inhibitors, hormones, folinic acid, leucovorin, tramadol, and tryptophan in combination with an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of a typical antipsychotic drug, an atypical antipsychotic drug, and a dopamine system stabilizer.

127 (New): A method for treatment of a patient having cognitive distortions with functional impairment or health hazards, wherein said patient is suffering from major depressive disorder, wherein said major depressive disorder categorized as non-treatment resistant and non-psychotic, wherein the method comprising administering to said patient an antipsychotic drug, wherein said antipsychotic drug is selected from the group consisting of an atypical antipsychotic drug, and a dopamine system stabilizer and wherein said treatment is effected for resisting suicide.

128 (New): The method of Claim 127, wherein said treatment is effected for at least one of the group consisting of avoiding a paradoxical effect of antidepressant sensitizing patients to depression; treating a paradoxical effect of antidepressant sensitizing patients to depression; for avoiding worsening of depression from the antidepressant; and treating worsening of depression from the antidepressant.

129. (New): The method of Claim 127, wherein said treatment is effected at a time selected from the group consisting of, as an initial treatment, as soon as possible and upon presentation of said patient to a physician or other health care provider, and wherein said atypical antipsychotic drug or said dopamine system stabilizer is administered at a low dose.

130. (New): The method of Claims 126, 127, 128, 130, wherein said atypical antipsychotic or said dopamine system stabilizer is selected from the group consisting of risperidone, quetiapene, olanzapine, ziprasidone and aripiprazole, and the effective amount is from 0.5mg to 4mg for risperidone, from 25mg to 400mg for quetiapine, from 2.5mg to 10mg for olanzapine, from 10mg to 40 mg for ziprasidone, and 2.5mg to 15 mg for aripiprazole.